APR-2020

Phase 1Biologic

AApriligen, Inc.

APR-2020 is one of 8 biologic programs targeting Diamond-Blackfan anemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diamond-Blackfan AnemiaActive, not recruiting

Diamond-Blackfan AnemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Diamond-Blackfan Anemia

#DrugCompanyPhaseTrials

Rayos

Promacta

1 3

Neupogen

EEastern Cooperative Oncology Group

Bitopertin

1 5

G-CSF

AArog Pharmaceuticals, Inc.

Phase 2

1 6

Winrevair

Merck & Co.

Phase 1

—7

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 8

APR-2020

AApriligen, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Diamond-Blackfan Anemia

NCT07476183

Clinical

Trials by Indication[1]

Diamond-Blackfan anemia1 trial

Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia

Not yet recruiting·AApriligen, Inc.·Phase 1·NCT07476183·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APR-2020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APR-2020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APR-2020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apriligen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AApriligen, Inc.

APR-2020

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Diamond-Blackfan anemia1 trial

References

Drug Info

Quick Facts

Related News